This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
William Li and Danielle Chang, co-founders of The Hao Life, join Cheddar Innovates to discuss how they're shaking up the $71 billion supplement industry by putting a modern spin on traditional natural Chinese remedies.
The Coca-Cola Company is teaming up with science education personality Bill Nye as part of its World Without Waste Initiative to describe the bottle-to-bottle plastic recycling process through a vividly animated, stop-motion short film. Christine Yeager, director of sustainability at The Coca-Cola Company, North America, joined Cheddar News to talk about their initiative and the partnership. "We really wanted to partner with someone who can help us make recycling relatable, but also has a very um respected voice in the climate change space," she said.
Catching you up on what you need to know on Apr 14, 2022, with the U.S. sending $800M to Ukraine, updates on the subway shooting in Brooklyn, Gov. Abbott putting a pause on his southern border truck inspections, migrants being bused from Texas to Washington, DC, the travel mask mandate extending until May 3, and more.
Energy costs continue to rise, our electrical grid is outdated, and the focus on renewable energy is more important than ever. One company says it has an answer: pods that store solar energy for long-term, 24-hour usage that can also function as mini power grids and charge electric vehicles. Azelio's TES.PODs store solar energy during the day, and hold it for use around the clock, providing a solution for charging electric vehicles, powering rural areas, and much more. Jonas Wallmander, CEO of Azelio, joins Closing Bell to discuss the company's solar energy storage technology, how it can be used to power communities and build out electric vehicle charging infrastructure, and more.
Catching you up with what you need to know on Apr 12, 2022, with Russia concentrating forces in eastern Ukraine, rising inflation, severe weather from Minnesota to the Gulf Coast, Philadelphia brings back its indoor mask mandate, PG&E pays $55 million for wildfire settlement, and more
Catching you up on what you need to know on April 11, 2022, with updates on the Russia-Ukraine War, France’s presidential election, the record deforestation of the Amazon Rainforest, retail giant Amazon's objection to the Staten Island union vote, the worsening baby formula shortage, a lawsuit against Rutgers Law School, and a stomach illness possibly linked to Lucky Charms cereal.
SpaceX launched its first all commercial-crew mission to the International Space Station on Friday. Cheddar News speaks with Jim Cantrell, CEO and President of Phantom Space Corporation why this launch is a big leap for space tourism.
Nautilus Labs closed $34 million in funding from investors including the Microsoft Climate Innovation Fund. The company plans to use its funding to improve shipping industry efficiency with its software. Nautilus CEO Matt Heider joined Cheddar News to talk about how it tackles the carbon emissions in the global supply chain. "We've seen on 10-day voyages saving $60,000 worth of fuel just by managing speed with greater confidence around the future. The environmental impact of that is also huge," he said. "Saving that amount of fuel is a kind of taking over 1000 cars off the road this year."
